Claims for Patent: 8,013,128

Summary for Patent: 8,013,128

Title:	Antibodies and related molecules that bind to PSCA proteins
Abstract:	Antibodies and molecules derived therefrom that bind to novel PSCA protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with PSCA can be used in active or passive immunization.
Inventor(s):	Gudas; Jean (Los Angeles, CA), Jakobovits; Aya (Beverly Hills, CA), Jia; Xiao-chi (Los Angeles, CA), Morrison; Robert Kendall (Santa Monica, CA), Morrison; Karen Jane Meyrick (Santa Monica, CA), Shao; Hui (Los Angeles, CA), Challita-Eid; Pia M. (Encino, CA), Raitano; Arthur B. (Los Angeles, CA)
Assignee:	Agensys, Inc. (Santa Monica, CA)
Application Number:	12/397,992
Patent Claims:	1. A monoclonal antibody or fragment thereof comprising an antigen binding site that binds specifically to a PSCA protein comprising the amino acid sequence of SEQ ID NO:2, wherein the fragment is a Fab or F(ab').sub.2 fragment, and wherein the monoclonal antibody comprises the amino acid sequence of the V.sub.H region of SEQ ID NO: 47 and the V.sub.L region of SEQ ID NO: 51. 2. The monoclonal antibody or fragment thereof of claim 1, wherein the antibody is coupled to a detectable marker, a toxin, a therapeutic agent, or a chemotherapeutic agent. 3. The monoclonal antibody or fragment thereof of claim 2, wherein the detectable marker is a radioisotope, a metal chelator, an enzyme, a fluorescent compound, a bioluminescent compound or a chemiluminescent compound. 4. The monoclonal antibody or fragment thereof of claim 3, wherein the radioisotope comprises .sup.212Bi, .sup.131I, .sup.90Y, .sup.186Re, .sup.211At, .sup.125I, .sup.188Re, .sup.153Sm, .sup.213Bi, .sup.32P, or Lu. 5. The monoclonal antibody or fragment thereof of claim 2, wherein the toxin comprises ricin, ricin A chain, doxorubicin, daunorubicin, a maytansinoid, taxol, ethidium bromide, mitomycin, etoposide, tenopo side, vincristine, vinblastine, colchicine, dihydroxy anthracin dione, actinomycin, diphtheria toxin, Pseudomonas exotoxin (PE) A, PE40, abrin, abrin A chain, modeccin A chain, alpha sarcin, gelonin, mitogellin, restrictocin, phenomycin, enomycin, curicin, crotin, calicheamicin, sapaonaria officinalis inhibitor, glucocorticoid, auristatins, auromycin, yttrium, bismuth, combrestatin, duocarmycins, dolastatin, cc1065, or a cisplatin. 6. A pharmaceutical composition that comprises the monoclonal antibody or fragment thereof of claim 1. 7. A method of inhibiting tumor cell growth, comprising: administering to a patient in need thereof a monoclonal antibody or antigen binding fragment thereof in conjunction with administration of a chemotherapeutic agent, radiation or both, wherein the monoclonal antibody or antigen binding fragment thereof comprises an antigen binding site that binds specifically to a PSCA protein comprising the amino acid sequence of SEQ ID NO:2, and wherein the monoclonal antibody or antigen binding fragment thereof comprises the amino acid sequence of the V.sub.H region of SEQ ID NO: 47 and the V.sub.L region of SEQ ID NO: 51. 8. The method of claim 7, wherein the monoclonal antibody is administered before, during, or after commencing administration of the chemotherapeutic agent. 9. The method of claim 7, wherein the monoclonal antibody is administered before, during, or after commencing radiation therapy. 10. The method of claims 8 or 9, wherein the monoclonal antibody is administered between 1 and 60 days before commencing radiation therapy and/or chemotherapy. 11. The method of claim 7, wherein the chemotherapeutic agent is selected from the group consisting of cisplatin, dacarbazine (DTIC), dactinomycin, mechlorethamine (nitrogen mustard), streptozocin, cyclophosphamide, carmustine (BCNU), lomustine (CCNU), doxorubicin (adriamycin), daunorubicin, procarbazine, mitomycin, cytarabine, etoposide, methotrexate, 5-fluorouracil, vinblastine, vincristine, bleomycin, paclitaxel (taxol), docetaxel (taxotere), aldesleukin, asparaginase, busulfan, carboplatin, cladribine, dacarbazine, floxuridine, fludarabine, hydroxyurea, ifosfamide, interferon alpha, leuprolide, megestrol, melphalan, mercaptopurine, plicamycin, mitotane, pegaspargase, pentostatin, pipobroman, streptozocin, tamoxifen, teniposide, testolactone, thioguanine, thiotepa, uracil mustard, vinorelbine, chlorambucil, and combinations thereof. 12. The method of claim 11, further comprising the administration of an additional chemotherapeutic agent. 13. The method of claim 7, wherein the tumor cell is a prostate cancer tumor cell, a pancreatic cancer tumor cell, or a bladder cancer tumor cell. 14. A kit comprising: a container, a composition contained therein, and a package insert or label indicating that the composition can be used to inhibit growth of a cancer cell that expresses a PSCA protein comprising the amino acid sequence of SEQ ID NO:2, wherein the composition comprises the antibody of claim 1. 15. The kit of claim 14, wherein the cancer is a prostate cancer, pancreatic cancer, or bladder cancer. 16. A method of treating a cancer that expresses a PSCA protein, comprising: administering to a patient in need thereof a monoclonal antibody or antigen binding fragment thereof in conjunction with administration of a chemotherapeutic agent, radiation or both, wherein the monoclonal antibody or antigen binding fragment thereof comprises an antigen binding site that binds specifically to a PSCA protein on a cancer cell comprising the amino acid sequence of SEQ ID NO:2, and wherein the monoclonal antibody or antigen binding fragment thereof comprises the amino acid sequence of the V.sub.H region of SEQ ID NO: 47 and the V.sub.L region of SEQ ID NO: 51. 17. The method of claim 16, wherein the monoclonal antibody is administered before, during, or after commencing administration of the chemotherapeutic agent. 18. The method of claim 16, wherein the monoclonal antibody is administered before, during, or after commencing radiation therapy. 19. The method of claims 17 or 18, wherein the monoclonal antibody is administered between 1 and 60 days before commencing radiation therapy and/or chemotherapy. 20. The method of claim 16, wherein the chemotherapeutic agent is selected from the group consisting of cisplatin, dacarbazine (DTIC), dactinomycin, mechlorethamine (nitrogen mustard), streptozocin, cyclophosphamide, carmustine (BCNU), lomustine (CCNU), doxorubicin (adriamycin), daunorubicin, procarbazine, mitomycin, cytarabine, etoposide, methotrexate, 5-fluorouracil, vinblastine, vincristine, bleomycin, paclitaxel (taxol), docetaxel (taxotere), aldesleukin, asparaginase, busulfan, carboplatin, cladribine, dacarbazine, floxuridine, fludarabine, hydroxyurea, ifosfamide, interferon alpha, leuprolide, megestrol, melphalan, mercaptopurine, plicamycin, mitotane, pegaspargase, pentostatin, pipobroman, streptozocin, tamoxifen, teniposide, testolactone, thioguanine, thiotepa, uracil mustard, vinorelbine, chlorambucil, and combinations thereof. 21. The method of claim 20, further comprising the administration of an additional chemotherapeutic agent. 22. The method of claim 16, wherein the cancer cell is a prostate cancer cell, a pancreatic cancer cell, or a bladder cancer cell.

Details for Patent 8,013,128

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2039-02-26
Clinigen, Inc.	PROLEUKIN	aldesleukin	For Injection	103293	05/05/1992		2039-02-26
Servier Pharmaceuticals Llc	ONCASPAR	pegaspargase	Injection	103411	02/01/1994		2039-02-26